[HTML][HTML] Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
JM Michot, J Lazarovici, A Tieu, S Champiat… - European Journal of …, 2019 - Elsevier
Immune checkpoint inhibitors (ICIs) are changing the treatments of many patients with
cancer. These immunotherapies are generally better tolerated than chemotherapy, and their …
cancer. These immunotherapies are generally better tolerated than chemotherapy, and their …
Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and …
GE Tanios, PB Doley, R Munker - European journal of …, 2019 - Wiley Online Library
Background Immune checkpoint inhibitors (CPI) are widely used in modern oncology and
have improved the prognosis of lung cancer, malignant melanoma, and other malignancies …
have improved the prognosis of lung cancer, malignant melanoma, and other malignancies …
Influence of granulocyte-colony-stimulating factor on the cytological picture of the wound in patients with purulent-inflammatory diseases of soft tissues on the …
AO Okhunov - 2022 - researchsquare.com
Background. Purulent-inflammatory diseases of soft tissues in patients with diabetes mellitus
proceeds quite aggressively and, according to the standards, characteristic of acute …
proceeds quite aggressively and, according to the standards, characteristic of acute …
[PDF][PDF] Morphological aspects of wounds in patients with purulent inflammation of soft tissues in diabetes mellitus and under the influence of granulocytecolony …
UI Pulatov, RI Israilov, AO Okhunov… - 2022 - repository.tma.uz
Background. Purulent-inflammatory diseases of soft tissues in patients with diabetes mellitus
proceeds quite aggressively and, according to the standards, characteristic of acute …
proceeds quite aggressively and, according to the standards, characteristic of acute …
Invasive fungal diseases in children with hematological malignancies treated with therapies that target cell surface antigens: monoclonal antibodies, immune …
Since 1985 when the first agent targeting antigens on the surface of lymphocytes was
approved (muromonab-CD3), a multitude of such therapies have been used in children with …
approved (muromonab-CD3), a multitude of such therapies have been used in children with …
Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect
J Boegeholz, CS Brueggen, C Pauli, F Dimitriou… - BMC cancer, 2020 - Springer
Background Cancer immunotherapy via immune-checkpoint inhibition (ICI) by antibodies
against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and cell death protein 1 (PD …
against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and cell death protein 1 (PD …
Management and outcomes of hematological immune-related adverse events: systematic review and meta-analysis
NR Wilson, JR Lockhart… - Journal of …, 2022 - journals.lww.com
Data regarding clinical outcomes and management of hematological manifestations of
immune checkpoint inhibition (ICI) is limited to case reports, series, and a few retrospective …
immune checkpoint inhibition (ICI) is limited to case reports, series, and a few retrospective …
Immune thrombocytopenia induced by immune checkpoint inhibitrs in lung cancer: case report and literature review
W Xie, NN Hu, LJ Cao - Frontiers in Immunology, 2021 - frontiersin.org
Immune checkpoint inhibitors (ICIs), including antibodies targeting programmed cell death
protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1), are being extensively used …
protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1), are being extensively used …
Fungal infection risks associated with the use of cytokine antagonists and immune checkpoint inhibitors
X Li, SKP Lau, PCY Woo - Experimental Biology and …, 2020 - journals.sagepub.com
The revolutionary success of biologic agents in treating various malignant and autoimmune
conditions has been met with increased risk of opportunistic infections due to perturbations …
conditions has been met with increased risk of opportunistic infections due to perturbations …
Fungal infections associated with the use of novel immunotherapeutic agents
M Bernardes, TM Hohl - Current clinical microbiology reports, 2020 - Springer
Abstract Purpose of the Review Recent concerns have emerged regarding the potential of
immunotherapy to cause infection. In this review, we summarize the current literature on …
immunotherapy to cause infection. In this review, we summarize the current literature on …